BioLine RX Ltd (BLRX) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.108x

Based on the latest financial reports, BioLine RX Ltd (BLRX) has a cash flow conversion efficiency ratio of -0.108x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-2.11 Million ≈ $-5.65K USD) by net assets (ILA19.53 Million ≈ $52.37K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of BioLine RX Ltd for the company's overall valuation and market capitalisation.

BioLine RX Ltd - Cash Flow Conversion Efficiency Trend (2010–2024)

This chart illustrates how BioLine RX Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

BioLine RX Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of BioLine RX Ltd ranked by their cash flow conversion efficiency. Explore BioLine RX Ltd (BLRX) cash earnings ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
RUGBY RESOURCES LTD F:64O	N/A
Danish Aerospace Company A/S CO:DAC	0.428x
Jwwinvest WAR:JWW	0.098x
Radiant Utama Interinsco Tbk JK:RUIS	0.083x
Savannah Goldfields Ltd AU:SVG	-0.584x
PHOENIX NEW MED.ADR 1/48 F:1PX	N/A
Lions Bay Capital Inc V:LBI	-0.065x
Trainline Plc LSE:TRN	0.441x

Annual Cash Flow Conversion Efficiency for BioLine RX Ltd (2010–2024)

The table below shows the annual cash flow conversion efficiency of BioLine RX Ltd from 2010 to 2024. View BioLine RX Ltd (BLRX) stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	ILA13.46 Million ≈ $36.09K	ILA-43.87 Million ≈ $-117.62K	-3.259x	-90.63%
2023-12-31	ILA13.22 Million ≈ $35.45K	ILA-22.61 Million ≈ $-60.61K	-1.710x	-231.27%
2022-12-31	ILA50.84 Million ≈ $136.30K	ILA-26.24 Million ≈ $-70.35K	-0.516x	-49.07%
2021-12-31	ILA68.09 Million ≈ $182.54K	ILA-23.57 Million ≈ $-63.20K	-0.346x	+67.13%
2020-12-31	ILA22.03 Million ≈ $59.06K	ILA-23.21 Million ≈ $-62.21K	-1.053x	-55.13%
2019-12-31	ILA33.38 Million ≈ $89.49K	ILA-22.67 Million ≈ $-60.77K	-0.679x	-15.98%
2018-12-31	ILA41.32 Million ≈ $110.78K	ILA-24.19 Million ≈ $-64.86K	-0.585x	-50.68%
2017-12-31	ILA52.88 Million ≈ $141.77K	ILA-20.55 Million ≈ $-55.09K	-0.389x	+6.22%
2016-12-31	ILA35.03 Million ≈ $93.91K	ILA-14.51 Million ≈ $-38.91K	-0.414x	-39.23%
2015-12-31	ILA47.61 Million ≈ $127.64K	ILA-14.17 Million ≈ $-37.98K	-0.298x	+34.72%
2014-12-31	ILA31.77 Million ≈ $85.16K	ILA-14.48 Million ≈ $-38.82K	-0.456x	+73.68%
2013-12-31	ILA11.68 Million ≈ $31.32K	ILA-20.23 Million ≈ $-54.25K	-1.732x	-28.90%
2012-12-31	ILA14.97 Million ≈ $40.14K	ILA-20.11 Million ≈ $-53.93K	-1.344x	-169.77%
2011-12-31	ILA22.53 Million ≈ $60.41K	ILA-11.22 Million ≈ $-30.09K	-0.498x	-673.33%
2010-12-31	ILA131.96 Million ≈ $353.78K	ILA11.46 Million ≈ $30.73K	0.087x	--

About BioLine RX Ltd

TA:BLRX Israel Biotechnology

Market Cap

$9.10 Million

ILA3.39 Billion ILA

Market Cap Rank

#27406 Global

#389 in Israel

Share Price

ILA1.30

Change (1 day)

+0.00%

52-Week Range

ILA1.20 - ILA2.30

All Time High

ILA618.30